AI assistant
ABBOTT LABORATORIES — Director's Dealing 2014
Feb 25, 2014
29777_rns_2014-02-25_27edd557-1a45-4a3f-94cd-9aa0c07a4b5b.pdf
Director's Dealing
Open in viewerOpens in your device viewer
Page 1 of 1
SEC FORM 4
SEC Form 4
FORM 4
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
OMB APPROVAL
Washington, D.C. 20549
| OMB Number: 3235-0287 |
OMB Number: 3235-0287 |
OMB Number: 3235-0287 |
OMB Number: 3235-0287 |
OMB Number: 3235-0287 |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Check | this | box if no longer subject | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Expires: |
December 31, 2014 |
|||||||||||||
| to Section 16. Form 4 or Form 5 | Estimated average burden | ||||||||||||||||
| obligations Instruction |
may continue.See 1(b). |
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
hours per response: |
0.5 | |||||||||||||
| 1. Name and Address of Reporting Person* Pavee Jean-Yves |
2. Issuer NameandTicker or Trading Symbol ABBOTT LABORATORIES[ABT] |
5. Relationship of Reporting (Check all applicable) Director |
Person(s) to Issuer 10% Owner |
||||||||||||||
| (Last) (First) 100 ABBOTT PARK ROAD |
(Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 02/21/2014 |
X | Officer (give title below) Senior Vice |
Other (specify below) President |
||||||||||||
| 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable | ||||||||||||||||
| (Street) | Line) | ||||||||||||||||
| ABBOTT PARK |
IL | 60064 | X | Form filed by One Reporting Person Form filed by More than One Reporting |
|||||||||||||
| Person | |||||||||||||||||
| (City) | (State) | (Zip) | |||||||||||||||
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially | Owned | ||||||||||||||||
| 1. Title of | Security (Instr. 3) | 2. Transaction Date 2A. Deemed Execution Date, |
3. Transaction |
4. Securities Acquired (A) or Disposed Of (D) |
5. Amount of Securities |
6. Ownership |
7. Nature of Indirect |
||||||||||
| (Month/Day/Year) if any |
Code (Instr. | (Instr. 3, 4 and 5) | Beneficially | Form: | Beneficial | ||||||||||||
| (Month/Day/Year) | 8) | Owned | Direct (D) or | Ownership | |||||||||||||
| Following | Indirect (I) | (Instr. | 4) | ||||||||||||||
| (A) | Reported | (Instr. 4) | |||||||||||||||
| Code V |
Amount | or | Price | Transaction(s) | |||||||||||||
| (D) | (Instr. 3 and 4) | ||||||||||||||||
| Table II - Derivative Securities Acquired, Disposed of, | or Beneficially | Owned | |||||||||||||||
| (e.g., puts, calls, warrants, options, | convertible securities) | ||||||||||||||||
| 1. Title of | 2. | 3. Transaction | 3A. Deemed | 4. | 5. Number 6. Date Exercisable and |
7. Title and | Amount | 8. Price of 9. Number |
10. | 11. Nature | |||||||
| Derivative | Conversion |
Date | Execution Date, | Transaction | of Expiration Date |
of Securities | Derivative of |
Ownership | of Indirect |
||||||||
| Security | or Exercise | (Month/Day/Year) | if any | Code (Instr. | Derivative (Month/Day/Year) |
Underlying | Security derivative |
Form: | Beneficial | ||||||||
| (Instr. 3) | Price of | (Month/Day/Year) | 8) | Securities | Derivative Security | (Instr. 5) Securities |
Direct (D) | Ownership | |||||||||
| Derivative | Acquired | (Instr. 3 and 4) | Beneficially | or Indirect | (Instr. 4) | ||||||||||||
| Security | (A) or | Owned | (I) (Instr. 4) | ||||||||||||||
| Disposed | Following | ||||||||||||||||
| of (D) | Reported | ||||||||||||||||
| (Instr. 3, 4 | Transaction | ||||||||||||||||
| and 5) | (s) (Instr. 4) | ||||||||||||||||
| Amount | |||||||||||||||||
| or | |||||||||||||||||
| Number | |||||||||||||||||
| Date | Expiration | of | |||||||||||||||
| Code V |
(A) (D) Exercisable |
Date | Title | Shares | |||||||||||||
| Option (right to buy) (1) |
$39.12 | 02/21/2014 | A | 81,940 02/21/2015 |
02/20/2024 | Common shares |
81,940 | $0 81,940 |
D |
Explanation of Responses:
- Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,314 on 2/21/2015, 27,313 on 2/21/2016, and 27,313 on 2/21/2017.
John A. Berry, by power ofattorney for Jean-Yves Pavee 02/25/2014
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
-
If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
-
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
2/25/2014